Natixis Advisors
APGE icon

Natixis Advisors’s Apogee Therapeutics APGE Stock Holding History

Natixis Advisors’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,475
Closed -$496K – 1595
2025
Q3 		$496K Sell
12,475
-2,556
-17% -$97.6K ﹤0.01% 1493
2025
Q2 		$653K Buy
15,031
+15
+0.1% +$571 ﹤0.01% 1419
2025
Q1 		$561K Buy
15,016
+238
+2% +$9.2K ﹤0.01% 1431
2024
Q4 		$669K Sell
14,778
-190
-1% -$9.69K ﹤0.01% 1406
2024
Q3 		$879K Buy
+14,968
New +$717K ﹤0.01% 1333

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Natixis Advisors's APGE Position: Q4 2025 in Review

Natixis Advisors sold out of Apogee Therapeutics (APGE) in Q4 2025, closing a stake of 12,475 shares — an estimated $496K sold.

Natixis Advisors first reported a position in APGE in Q3 2024 and held it in 5 quarters. The position peaked at $879K in Q3 2024. 206 funds tracked by Wall St. Rank hold APGE as of Q4 2025.

  • Natixis Advisors reported no remaining Apogee Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Natixis Advisors sold 12,475 Apogee Therapeutics shares in Q4 2025, an estimated $496K.
  • Natixis Advisors first reported a position in Apogee Therapeutics in Q3 2024 and held it in 5 quarters.
  • Natixis Advisors's Apogee Therapeutics position peaked at $879K in Q3 2024.
  • 206 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q4 2025.

Based on Natixis Advisors's 13F filing for Q4 2025, filed 10 Feb 2026.